Search
Cyclosporine
go.drugbank.com/drugs/DB00091ApprovedInvestigationalVet approved[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Etripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational[A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.
Elivaldogene autotemcel
go.drugbank.com/drugs/DB16746Approved[L40298] In September 2022, Skysona was approved by the FDA.[L43247] … [A243691] Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs.
Boldenone
go.drugbank.com/drugs/DB01541ExperimentalIllicitVet approvedIt is not indicated for use in humans in the US and is only available through veterinary clinics.
Valrubicin
go.drugbank.com/drugs/DB00385ApprovedUsed in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.
Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigational[A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).